CMIC Holdings Co Ltd represents a strong set of values and corporate philosophy. As a leading stock company, CMIC Holdings Co Ltd prioritizes integrity, innovation, and client satisfaction. With a commitment to excellence, CMIC Holdings Co Ltd aims to provide cutting-edge stock solutions and build strong partnerships with investors. The company values transparency, professionalism, and continuous growth. By leveraging their expertise and advanced technology, CMIC Holdings Co Ltd strives to deliver optimal financial services, thereby contributing to the success and prosperity of its clients.

CMIC Holdings Co Ltd is primarily present in Japan.

CMIC Holdings Co Ltd has achieved several significant milestones. One key milestone for the company was the establishment of its subsidiary CMIC Healthcare Co Ltd in 2013, which allowed CMIC Holdings to expand into the healthcare industry. Additionally, in 2016, CMIC Holdings Co Ltd successfully listed its shares on the Tokyo Stock Exchange, marking another important milestone in the company's history. Moreover, CMIC Holdings has been recognized globally for its innovative drug development services and has received numerous industry awards and accolades. These achievements reflect the company's strong growth and commitment to delivering high-quality services in the pharmaceutical and healthcare sectors.

CMIC Holdings Co Ltd, established in 1992, is a leading Japanese company specializing in providing comprehensive clinical development services in the pharmaceutical and medical field. With a rich history spanning nearly three decades, CMIC has successfully built a strong reputation through its commitment to quality, innovation, and customer satisfaction. The company offers a wide range of services, including clinical trials, regulatory affairs, medical affairs, and strategic consultancy. With a dedicated team of experts and cutting-edge technology, CMIC is well-positioned to support pharmaceutical companies throughout their product development journey. With its exceptional track record and industry expertise, CMIC Holdings Co Ltd has become a trusted partner in Japan's pharmaceutical sector.

The main competitors of CMIC Holdings Co Ltd in the market include Quintiles IMS Holdings Inc., ICON plc, and Pharmaceutical Product Development (PPD) Inc. These companies are prominent players in the contract research organization (CRO) industry, which is CMIC Holdings' primary market segment. CMIC Holdings Co Ltd faces tough competition from these industry-leading firms in providing comprehensive clinical trial and research services, regulatory consulting, and quality assurance solutions. Maintaining a strong market position requires CMIC Holdings' continuous focus on innovation, exceptional client service, and delivering highly efficient and cost-effective solutions to pharmaceutical, biotechnology, and medical device companies.

CMIC Holdings Co Ltd is primarily active in the industries of contract research organization (CRO) services, clinical development, and pharmaceutical development.

CMIC Holdings Co Ltd is a Japanese company with a unique business model in the healthcare industry. The company offers a comprehensive range of contract research and development (R&D) services to pharmaceutical, biotechnology, and medical device companies. CMIC Holdings Co Ltd focuses on providing integrated solutions for the entire drug development process, including clinical trials, regulatory support, data management, and post-marketing studies. With its expertise and extensive network, the company plays a crucial role in accelerating the development and commercialization of new medicines and healthcare products. CMIC Holdings Co Ltd's business model emphasizes collaboration, efficiency, and innovation to meet the dynamic needs of the global healthcare market.

CMIC Holdings Co KGV ir 12,27.

CMIC Holdings Co KUV ir 0,58.

AlleAktien kvalitātes vērtējums CMIC Holdings Co ir 7/10.

gaidāmā CMIC Holdings Co apgrozījums ir 78,78 miljardi JPY.

gaidāmā CMIC Holdings Co peļņa ir 3,70 miljardi JPY.

CMIC Holdings Co Ltd is a Japanese company that offers a wide range of services in the healthcare industry. The company is based in Tokyo and has been active for over 30 years. CMIC provides support in areas such as drug development, clinical trials, regulatory and health-related market research, and pharmaceutical distribution logistics. The company's product range is diverse and includes both consulting and operational services. One of the main business sectors is drug development, where the company offers a full-service platform that covers all necessary steps from preclinical development to approval and market launch of a drug. This includes safety and efficacy testing of drugs, competition analysis, dossier submission to regulatory authorities, and clinical trial logistics. Another important offering from CMIC is the conduct of clinical trials. The company takes care of planning, conducting, and analyzing studies in Japan and the US. To support study coordination, CMIC also provides a digital platform that facilitates data exchange with study centers. Regulatory Affairs is another business sector of CMIC, where the company offers support for submission of approval applications. This includes checking approval dossiers, collaborating with regulatory authorities, and monitoring risks and product recalls. CMIC also provides health-related market research, conducting investigations into specific diseases as well as markets for medical devices, diagnostics, and drugs. CMIC is also active in this field as a provider of big data analysis to optimize the healthcare industry as a whole. Pharmaceutical logistics is another important sector of CMIC. The company operates its own warehousing and offers handling services for the import and export of drugs and medical devices. CMIC also handles the direct shipment of drugs to clinics and pharmacies. In addition to the mentioned business sectors, CMIC also offers customer services for its entire product range. Customers can choose customized solutions tailored to the needs of their companies. CMIC also provides tailored support for the development of marketing strategies. Overall, CMIC is a comprehensive service provider in the healthcare industry. The company has expanded internationally in recent years and offers its services in other countries such as the US. With its wide portfolio, the company is well-positioned to meet the growing demands of the healthcare market.

CMIC Holdings Co izmaksā dividendes 15,00 JPY, kas tiek izmaksātas reizes gadā.

Dividendes pašlaik nevar aprēķināt CMIC Holdings Co vai uzņēmums nedod dividendes.

CMIC Holdings Co ISIN ir JP3359000001.

CMIC Holdings Co WKN ir 663202.

CMIC Holdings Co simbols ir 2309.T.

Pēdējo 12 mēnešu laikā CMIC Holdings Co maksāja dividendes 50,00 JPY apmērā. Tas atbilst aptuveni 1,89 % dividendes ražībai. Nākamajos 12 mēnešos CMIC Holdings Co plāno maksāt dividendes 61,39 JPY apmērā.

CMIC Holdings Co pašreizējā dividendu rentabilitāte ir 1,89 %.

CMIC Holdings Co maksā dividendes ceturksnī. Tās tiek izmaksātas mēnešos aprīlis, oktobris, aprīlis, oktobris.

CMIC Holdings Co pēdējo 23 gadu laikā katru gadu izmaksāja dividendes.

Nākamajiem 12 mēnešiem tiek prognozētas dividendes apmērā 61,39 JPY. Tas atbilst dividendes ražībai 2,32 %.

CMIC Holdings Co tiek piešķirts nozarei "Veselība".

Lai saņemtu pēdējo dividendu CMIC Holdings Co apmērā 45 JPY, kas tika izmaksāta 1.12.2023., tev akcija bija jāpatur depozītā līdz Ekss dienai, kas bija 28.09.2023..

Pēdējās dividendes izmaksa notika 1.12.2023..

Gadā 2023, CMIC Holdings Co izmaksāja 15 JPY dividendes.

CMIC Holdings Co dividendes tiek izmaksātas JPY.